WallStSmart
NEO

NeoGenomics Inc

NASDAQ: NEO · HEALTHCARE · DIAGNOSTICS & RESEARCH

$8.96
-0.67% today

Updated 2026-04-29

Market cap
$1.17B
P/E ratio
P/S ratio
1.60x
EPS (TTM)
$-0.84
Dividend yield
52W range
$5 – $14
Volume
2.1M

WallStSmart proprietary scores

51
out of 100
Grade: C
Hold
Investment rating
8.0
Growth
A
5.3
Quality
C+
2.0
Profitability
F
6.3
Valuation
B
3/9
Piotroski F-Score
Weak
1.0
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target
$13.81
+54.13%
12-Month target
Intrinsic (DCF)
$54.68
Margin of safety
+79.06%
2 Strong Buy4 Buy7 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Revenue growth 10.60% QoQ
+ 79.06% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 0.98 — distress zone
- Thin margins at -14.80%
- Negative free cash flow $-13.14M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$509.73M$591.64M$660.57M$727.33M$727.33M
Net income$-144.25M$-87.97M$-78.73M$-108.03M$-17.11M
EPS$-0.84
Free cash flow$-96.88M$-30.70M$-34.04M$-21.78M$-13.14M
Profit margin-28.30%-14.87%-11.92%-14.85%-14.80%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
NEO$1.17B518.02.06.35.3+79.06%Buy
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

NeoGenomics Inc trades at $8.96. Our Smart Value Score of 51/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.98, it sits in the distress. TTM revenue stands at $727.33M. with profit margins at -14.80%. Our DCF model estimates intrinsic value at $54.68.

Frequently asked questions

What is NeoGenomics Inc's stock price?
NeoGenomics Inc (NEO) trades at $8.96.
Is NeoGenomics Inc overvalued?
Smart Value Score 51/100 (Grade C, Hold). DCF value $54.68.
What is the price target of NeoGenomics Inc (NEO)?
The analyst target price is $13.81, representing +54.1% upside from the current price of $8.96.
What is the intrinsic value of NeoGenomics Inc (NEO)?
Based on our DCF model, intrinsic value is $54.68, a +79.1% margin of safety versus $8.96.
What is NeoGenomics Inc's revenue?
TTM revenue is $727.33M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
0.98 — distress.

Company info

SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio1.60x
ROE-12.40%
Beta1.71
50D MA$8.57
200D MA$9.38
Shares out0.13B
Float0.12B
Short ratio
Avg volume2.1M

Performance

1 week-0.13%
1 month-18.76%
3 months-34.10%
YTD-34.10%
1 year
3 years
5 years